Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tisotumab vedotin versus investigator's choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer
NL-OMON60530Phase 3Completed
- Sponsor
- Seagen Inc.
- Start
- Nov 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tisotumab vedotin in Cervical Cancer (CC), sponsored by Seagen Inc. Primary endpoint: Overall survival. Started Nov 2021; status: completed.
02
Drugs
tisotumab vedotin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NL-OMON60530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60530.